Jazz Pharmaceuticals (JAZZ) Assets Average (2011 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Assets Average of $11.8 billion for Q1 2026, little changed year-over-year from $11.8 billion in Q1 2025, and up 2.19% quarter-over-quarter from $11.5 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Assets Average (2011 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $11.8 billion for Q1 2026.
- In Q1 2026, Assets Average changed 0.12% year-over-year to $11.8 billion; the TTM figure through Mar 2026 stood at $11.8 billion (changed 0.12% YoY), while the FY2025 annual figure was $11.8 billion, up 1.14% from the prior year.
- Assets Average for Q1 2026 stood at $11.8 billion, up from $11.5 billion in the prior quarter.
- The five-year high for Assets Average was $12.1 billion in Q4 2024, with the low at $10.6 billion in Q4 2022.
- The 5-year median for Assets Average is $11.3 billion (2024), against an average of $11.4 billion.
- Peak annual rise in Assets Average reached 81.06% in 2022, while the deepest fall reached 15.98% in 2022.
- Jazz Pharmaceuticals' Assets Average stood at $10.6 billion in 2022, then gained by 6.49% to $11.3 billion in 2023, then grew by 7.39% to $12.1 billion in 2024, then slipped by 5.16% to $11.5 billion in 2025, then climbed by 2.19% to $11.8 billion in 2026.
- Business Quant data shows JAZZ's Assets Average at $11.8 billion in Q1 2026, $11.5 billion in Q4 2025, and $11.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 11.47 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.47 Bn |
| Mar 31, 2026 | 11.76 Bn |
| Dec 31, 2025 | 11.51 Bn |
| Sep 30, 2025 | 11.15 Bn |
| Jun 30, 2025 | 11.24 Bn |
| Mar 31, 2025 | 11.77 Bn |
| Dec 31, 2024 | 12.13 Bn |
| Sep 30, 2024 | 11.81 Bn |
| Jun 30, 2024 | 11.34 Bn |
| Mar 31, 2024 | 11.36 Bn |
| Dec 31, 2023 | 11.30 Bn |
| Sep 30, 2023 | 11.23 Bn |
| Jun 30, 2023 | 11.15 Bn |
| Mar 31, 2023 | 10.94 Bn |
| Dec 31, 2022 | 10.61 Bn |
| Sep 30, 2022 | 10.79 Bn |
| Jun 30, 2022 | 11.48 Bn |
| Mar 31, 2022 | 12.03 Bn |
| Dec 31, 2021 | 12.39 Bn |
| Sep 30, 2021 | 12.85 Bn |